title: A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines.
abstract: The 2013 cholesterol management guidelines presented a major shift in recommendations on which patients at risk of cardiovascular disease should be treated and how to treat them. Implementation of the guidelines is estimated to increase substantially the number of people who would be eligible for statin therapy. As the medical community considers the broad population impact of the new cholesterol guidelines, the issue of cost-effectiveness plays a role. This review covers the basic fundamentals of cost-effectiveness analysis and summarizes the key cost-effectiveness studies that relate to the new cholesterol guidelines.
authors: Weill Cornell Medicine College, New York-Presbyterian Hospital, 520 East 70th Street, ST 443, New York, NY, 10021, USA.
authors: Roderick C
authors: RC
authors: Deaño
authors: Ankur
authors: A
authors: Pandya
authors: Erica C
authors: EC
authors: Jones
authors: William B
authors: WB
authors: Borden
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000191:economics*; D002784:Cholesterol / Q000378:metabolism*; D003362:Cost-Benefit Analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol